Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ensemble Discovery, a developer of therapeutics and diagnostics, has extended its collaboration with Roche to apply its proprietary diagnostic technology to personalized cancer therapy.
Subscribe to our email newsletter
The collaboration will deploy Ensemble Discovery’s proprietary diagnostic assays in human clinical studies to analyze combinations of epidermal growth factor receptors (EGFR) present in cancer tissues. This family of receptors is said to be one of the most actively targeted in modern oncology therapy.
The goal of the project is to develop product prototypes that detect EGFR receptor dimers in human cancer tissue samples and ultimately to use those products to improve the management of cancer patients and their therapy.
David Livingston, senior vice president and head of the biodetection program at Ensemble Discovery, said: “We are now going to work with Roche to extend the panel of assays against various members of the EGFR family and advance those assays into clinical studies.
“Ensemble is committed to the deployment of our EGFR assays for optimal use of anti-EGFR therapy, and we view collaboration with Roche’s pharmaceutical and diagnostic groups as a unique route to achieve that goal.”